 From January 2006 GITIL Gruppo Italiano Terapie Innovative nei Linfomi suggested an early intensification of chemotherapy with BEACOPP Bleomycin, Etoposide, Adriamycin doxorubicin, Cyclophosphamide, Oncovin vincristine, Procarbazine, and Prednisone4 escalated 4 baseline cycles for all the HL patients with a positive PET-2 after 2 ABVD courses. The investigators retrospectively recorded and analyzed these data in order to evaluate if this strategy could be of benefit for this subset of patients. 